NeuroVive will fund the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly.
to-BBB CSO Pieter Gaillard said that the blood-brain barrier (BBB) is indeed a significant obstacle in the treatment of CNS disorders, to-BBB’s proprietary G-Technology can safely enhance drug delivery to the brain and they are excited to address this with NeuroVive’s cyclosporin-based pharmaceuticals.
NeuroVive CEO Mikael Bronnegard said that the deal with to-BBB has the potential to generate drugs for large markets in CNS diseases such as stroke.
to-BBB CEO Willem van Weperen said that they are convinced that synergies in research and clinical platforms as well as business and commercial strategies between to-BBB and NeuroVive will result in a strong partnership that will benefit patients with these CNS diseases.